NUVL – Nuvalent Inc
NUVL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.7
Margin Of Safety %
Put/Call OI Ratio
0.7
EPS Next Q Diff
-0.01
EPS Last/This Y
0.4
EPS This/Next Y
1.46
Price
102.11
Target Price
144.53
Analyst Recom
1.2
Performance Q
-0.85
Upside
-307.7%
Beta
1.14
Ticker: NUVL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | NUVL | 108.05 | 0.76 | 0.00 | 1473 |
| 2026-04-24 | NUVL | 104.87 | 0.76 | 0.00 | 1471 |
| 2026-04-27 | NUVL | 104.05 | 0.75 | 0.00 | 1484 |
| 2026-04-28 | NUVL | 101.99 | 0.75 | 999.99 | 1486 |
| 2026-04-29 | NUVL | 99.15 | 1.15 | 0.73 | 1825 |
| 2026-04-30 | NUVL | 100.18 | 1.15 | 0.73 | 1825 |
| 2026-05-01 | NUVL | 99.12 | 1.15 | 2.00 | 1832 |
| 2026-05-04 | NUVL | 102.61 | 1.14 | 0.00 | 1866 |
| 2026-05-05 | NUVL | 101.47 | 1.13 | 1.25 | 1870 |
| 2026-05-06 | NUVL | 104.26 | 1.14 | 0.13 | 1873 |
| 2026-05-07 | NUVL | 102.48 | 1.13 | 1.00 | 1880 |
| 2026-05-08 | NUVL | 105.3 | 1.13 | 0.00 | 1886 |
| 2026-05-11 | NUVL | 104.47 | 1.10 | 0.00 | 1908 |
| 2026-05-12 | NUVL | 102.62 | 1.07 | 1.50 | 1934 |
| 2026-05-13 | NUVL | 105.4 | 1.07 | 999.99 | 1934 |
| 2026-05-14 | NUVL | 104.45 | 1.07 | 999.99 | 1935 |
| 2026-05-15 | NUVL | 102.31 | 1.07 | 0.25 | 1936 |
| 2026-05-18 | NUVL | 99.99 | 1.07 | 0.25 | 1936 |
| 2026-05-19 | NUVL | 101.02 | 0.70 | 0.00 | 1551 |
| 2026-05-20 | NUVL | 102.24 | 0.70 | 0.00 | 1552 |
| 2026-05-21 | NUVL | 101.12 | 0.70 | 0.43 | 1554 |
| 2026-05-22 | NUVL | 101.9 | 0.70 | 0.02 | 1568 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | NUVL | 108.06 | -10.6 | 29.5 | -5.50 |
| 2026-04-24 | NUVL | 104.50 | -10.6 | 44.6 | -5.50 |
| 2026-04-27 | NUVL | 104.04 | -10.6 | 46.6 | -5.50 |
| 2026-04-28 | NUVL | 101.95 | -10.6 | 55.4 | -5.50 |
| 2026-04-29 | NUVL | 99.11 | -10.6 | 67.5 | -5.50 |
| 2026-04-30 | NUVL | 100.29 | -10.6 | 60.6 | -5.50 |
| 2026-05-01 | NUVL | 99.07 | -10.6 | 65.7 | -5.50 |
| 2026-05-04 | NUVL | 102.52 | -10.6 | 51.1 | -5.50 |
| 2026-05-05 | NUVL | 101.31 | -10.6 | 56.2 | -5.50 |
| 2026-05-06 | NUVL | 104.15 | -10.6 | 38.4 | -5.50 |
| 2026-05-07 | NUVL | 102.43 | -10.6 | 51.4 | -5.50 |
| 2026-05-08 | NUVL | 105.34 | -10.6 | 39.0 | -5.50 |
| 2026-05-11 | NUVL | 104.57 | -1.4 | - | -5.55 |
| 2026-05-12 | NUVL | 102.65 | 2.4 | - | -5.36 |
| 2026-05-13 | NUVL | 105.39 | 2.4 | - | -5.36 |
| 2026-05-14 | NUVL | 104.48 | 2.7 | - | -5.43 |
| 2026-05-15 | NUVL | 102.29 | 2.7 | - | -5.43 |
| 2026-05-18 | NUVL | 99.89 | 1.2 | - | -5.45 |
| 2026-05-19 | NUVL | 101.07 | 1.2 | - | -5.45 |
| 2026-05-20 | NUVL | 102.29 | 1.0 | - | -5.45 |
| 2026-05-21 | NUVL | 101.18 | 1.0 | - | -5.45 |
| 2026-05-22 | NUVL | 102.11 | 1.0 | - | -5.45 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | NUVL | -4.11 | 11.21 | 9.59 |
| 2026-04-24 | NUVL | -4.11 | 11.21 | 9.59 |
| 2026-04-27 | NUVL | -4.11 | 11.36 | 8.84 |
| 2026-04-28 | NUVL | -4.11 | 11.36 | 8.84 |
| 2026-04-29 | NUVL | -4.11 | 11.36 | 8.84 |
| 2026-04-30 | NUVL | -3.90 | 11.36 | 8.84 |
| 2026-05-01 | NUVL | -3.83 | 11.36 | 8.80 |
| 2026-05-04 | NUVL | -3.83 | 10.83 | 8.80 |
| 2026-05-05 | NUVL | -3.83 | 10.83 | 8.80 |
| 2026-05-06 | NUVL | -3.87 | 10.83 | 8.80 |
| 2026-05-07 | NUVL | -3.98 | 10.83 | 8.80 |
| 2026-05-08 | NUVL | -3.98 | 10.83 | 8.80 |
| 2026-05-11 | NUVL | -3.98 | 7.03 | 8.80 |
| 2026-05-12 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-13 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-14 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-15 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-18 | NUVL | -3.98 | 6.85 | 9.70 |
| 2026-05-19 | NUVL | -3.98 | 6.85 | 9.70 |
| 2026-05-20 | NUVL | -3.82 | 6.85 | 9.70 |
| 2026-05-21 | NUVL | -3.82 | 6.85 | 9.70 |
| 2026-05-22 | NUVL | -3.82 | 6.85 | 9.70 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.39
Avg. EPS Est. Current Quarter
-1.38
Avg. EPS Est. Next Quarter
-1.4
Insider Transactions
-3.82
Institutional Transactions
6.85
Beta
1.14
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
2
Fair Value
Quality Score
9
Growth Score
23
Sentiment Score
8
Actual DrawDown %
10
Max Drawdown 5-Year %
Target Price
144.53
P/E
Forward P/E
PEG
P/S
P/B
6.86
P/Free Cash Flow
EPS
-6.06
Average EPS Est. Cur. Y
-5.45
EPS Next Y. (Est.)
-3.99
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.01
Return on Equity vs Sector %
-65.4
Return on Equity vs Industry %
-49.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.05
EBIT Estimation
◆
NUVL
Healthcare
$102.12
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
48.7
Range 1M
35%
Sup Dist
2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
3.6%
EPS NY
22.4%
52W%
74%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+41.5% upside
Upside
+41.5%
Quality
9
Nuvalent, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 234
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL
Latest News
—
Caricamento notizie per NUVL…
stock quote shares NUVL – Nuvalent Inc Stock Price stock today
news today NUVL – Nuvalent Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NUVL – Nuvalent Inc yahoo finance google finance
stock history NUVL – Nuvalent Inc invest stock market
stock prices NUVL premarket after hours
ticker NUVL fair value insiders trading